1 Ocak 2023 Dergi makalesi Açık Erişim

Senol, Halil; Ozgun-Acar, Ozden; Dag, Aydan; Eken, Ahmet; Guner, Huseyin; Aykut, Zaliha Gamze; Topcu, Gulacti; Sen, Alaattin

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/273276</identifier>
  <creators>
    <creator>
      <creatorName>Senol, Halil</creatorName>
      <givenName>Halil</givenName>
      <familyName>Senol</familyName>
      <affiliation>Bezmialem Vakif Univ, Fac Pharm, Dept Pharmaceut Chem, TR-34093 Istanbul, Turkiye</affiliation>
    </creator>
    <creator>
      <creatorName>Ozgun-Acar, Ozden</creatorName>
      <givenName>Ozden</givenName>
      <familyName>Ozgun-Acar</familyName>
      <affiliation>Pamukkale Univ, Seed Breeding &amp; Genet Applicat Res Ctr, TR-20070 Denizli, Turkiye</affiliation>
    </creator>
    <creator>
      <creatorName>Dag, Aydan</creatorName>
      <givenName>Aydan</givenName>
      <familyName>Dag</familyName>
      <affiliation>Bezmialem Vakif Univ, Fac Pharm, Dept Pharmaceut Chem, TR-34093 Istanbul, Turkiye</affiliation>
    </creator>
    <creator>
      <creatorName>Eken, Ahmet</creatorName>
      <givenName>Ahmet</givenName>
      <familyName>Eken</familyName>
      <affiliation>Med Biol Erciyes Univ, Fac Med, Dept Basic Med Sci, TR-38039 Kayseri, Turkiye</affiliation>
    </creator>
    <creator>
      <creatorName>Guner, Huseyin</creatorName>
      <givenName>Huseyin</givenName>
      <familyName>Guner</familyName>
      <affiliation>Univ Abdullah Gul, Fac Life &amp; Nat Sci, Dept Mol Biol &amp; Genet, TR-38080 Kayseri, Turkiye</affiliation>
    </creator>
    <creator>
      <creatorName>Aykut, Zaliha Gamze</creatorName>
      <givenName>Zaliha Gamze</givenName>
      <familyName>Aykut</familyName>
      <affiliation>Bilkent Univ, Lab Anim Facil, TR-06800 Ankara, Turkiye</affiliation>
    </creator>
    <creator>
      <creatorName>Topcu, Gulacti</creatorName>
      <givenName>Gulacti</givenName>
      <familyName>Topcu</familyName>
      <affiliation>Bezmialem Vakif Univ, Fac Pharm, Dept Pharmacognosy &amp; Phytochemistry, TR-34093 Istanbul, Turkiye</affiliation>
    </creator>
    <creator>
      <creatorName>Sen, Alaattin</creatorName>
      <givenName>Alaattin</givenName>
      <familyName>Sen</familyName>
    </creator>
  </creators>
  <titles>
    <title>Synthesis And Comprehensive In Vivo Activity Profiling Of Olean-12-En-28-Ol, 3Β-Pentacosanoate In Experimental Autoimmune Encephalomyelitis: A Natural Remyelinating And Anti-Inflammatory Agent</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2023</publicationYear>
  <dates>
    <date dateType="Issued">2023-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/273276</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1021/acs.jnatprod.2c00798</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;Multiple sclerosis (MS) treatment has received much attention, yet there is still no certain cure. We herein investigate the therapeutic effect of olean-12-en-28-ol, 3 beta- pentacosanoate (OPCA) on a preclinical model of MS. First, OPCA was synthesized semisynthetically and characterized. Then, the mice with MOG35-55-induced experimental autoimmune/ allergic encephalomyelitis (EAE) were given OPCA along with a reference drug (FTY720). Biochemical, cellular, and molecular analyses were performed in serum and brain tissues to measure anti-inflammatory and neuroprotective responses. OPCA treat-ment protected EAE-induced changes in mouse brains maintaining blood-brain barrier integrity and preventing inflammation. Moreover, the protein and mRNA levels of MS-related genes such as HLD-DR1, CCL5, TNF-alpha, IL6, and TGFB1 were significantly reduced in OPCA-treated mouse brains. Notably, the expression of genes, including PLP, MBP, and MAG, involved in the development and structure of myelin was significantly elevated in OPCA-treated EAE. Furthermore, therapeutic OPCA effects included a substantial reduction in pro-inflammatory cytokines in the serum of treated EAE animals. Lastly, following OPCA treatment, the promoter regions for most inflammatory regulators were hypermethylated. These data support that OPCA is a valuable and appealing candidate for human MS treatment since OPCA not only normalizes the pro-and anti-inflammatory immunological bias but also stimulates remyelination in EAE.&lt;/p&gt;</description>
  </descriptions>
</resource>